Multimodal Biomarkers for Diagnosis and Prognosis in VCI
NCT ID: NCT04604600
Last Updated: 2020-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
120 participants
INTERVENTIONAL
2020-09-03
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. establish the correlation of plasma Aβ40 and Aβ42 level, ApoE genotype, MRI imaging markers in the diagnosis and prognosis of VCI patients
2. understand more on the pathophysiology of VCI.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. the correlation of clinical risk factors, ApoE genotype, various MRI markers, and amyloid PET expression
2. assess the influence of ApoE genotype on different biomarkers, including MRI markers, amyloid retention, and plasma Aβ40 and Aβ42 levels
3. the potential of amyloid PET as a prognostic factor for VCI patients.
Materials and methods This study will be conducted in National Taiwan University Hospital and Bei-Hu Branch Hospital. Sixty clinical diagnosed VCI, 30 AD patients and 30 normal subjects will be enrolled in this 3-year prospective study. We will collect vascular risk factors, neuropsychological tests, 10 cc venous blood for plasma Aβ40, Aβ42, total tau and phosphorylated level measurement by IMR assay, ApoE genotype, brain MRI, and amyloid PET of each patient and control subject. All the data will be analyzed together.
Expected Results We will try to
1. establish the correlation of plasma Aβ40 and Aβ42 level, ApoE genotype, MRI imaging markers in the diagnosis and prognosis of VCI patients
2. understand more on the pathophysiology of VCI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
amyloid PET、T807 PET
PET/CT
amyloid PET
Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
amyloid PET
Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
I. Vascular cognitive impairment patients:
1. Age older than 20 years.
2. Clinical diagnosis:
1. At least one obstacle to executive function, attention, memory, language and visual space function.
2. Affected activities of daily living.
3. Brain MRI showing cerebrovascular disease.
3. Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
II. Alzheimer's disease (AD) patients:
1. Age older than 20 years.
2. Clinical diagnosis:
1. Amnesia or non-amnesia (language, visual space, executive ability) performance.
2. Affected activities of daily living.
3. Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
III. Normal controls:
1. Age older than 20 years.
2. No neurological or psychiatric history.
3. Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
Exclusion Criteria
I. Vascular cognitive impairment patients:
1. Have other illnesses, including people with drug / alcohol abuse / addictivity within three months.
2. Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability.
3. Pregnant woman or intends to be pregnant in the near future.
4. Patient who is breast feeding or intends to.
5. Allergic to 11C-PiB, or with severe drug allergy history.
6. Patient or the family refuses to participate in the study.
II. Alzheimer's disease (AD) patients:
1. Have other illnesses, including:
1. Cognitive disorders caused by cerebrovascular diseases (the decline in cognitive function is closely related to the time of stroke, multiple large-scale necrosis, and severe white matter lesions).
2. The main manifestation of dementia is Lewy body dementia
3. Symptoms are behavioral variation of frontotemporal dementia.
4. The symptoms are obviously semantic progressive aphasia.
5. Symptoms are not fluent in primary progressive aphasia.
6. Other comorbidities that affect cognitive function (including other active neurological diseases, or non-neurological diseases but the disease or the treatment used will affect cognitive function)
2. Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability.
3. Pregnant woman or intends to be pregnant in the near future.
4. Patient who is breast feeding or intends to.
5. Allergic to 11C-PiB, or with severe drug allergy history.
6. Patient or the family refuses to participate in the study.
III. Normal controls:
1. Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability.
2. Pregnant woman or intends to be pregnant in the near future.
3. Patient who is breast feeding or intends to.
4. Allergic to 11C-PiB, or with severe drug allergy history.
5. Patient or the family refuses to participate in the study.
6. high risk as assessed by a doctor.
20 Years
99 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan Univeristy Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201912098MINB
Identifier Type: -
Identifier Source: org_study_id